111. 先天性ミオパチー Congenital myopathy Clinical trials / Disease details


臨床試験数 : 10 薬物数 : 17 - (DrugBank : 5) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 9

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05099107
(ClinicalTrials.gov)
October 25, 202115/10/2021Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no TreatmentCOMPIS- Congenital Myopathy Intervention Study. An Open-label, Cross Over, Randomised, Controlled Study Using Oral SalbutamolCongenital Myopathy;Neuromuscular Diseases;Musculoskeletal Diseases;Nemaline Myopathy;Centronuclear Myopathy;Myosin Storage MyopathyDrug: Salbutamol (as Salbutamol Sulfate) 2 Mg Oral Tablet;Drug: Salbutamol Only Product in Oral Dose FormVastra Gotaland RegionNULLEnrolling by invitation6 Years30 YearsAll20N/ASweden
2EUCTR2019-001147-51-SE
(EUCTR)
31/03/202027/09/2019This is a treatment study for a muscle disorder known as congenital myopathyCongenital myopathy intervention study - COMPIS Congenital myopathy
MedDRA version: 20.0;Level: PT;Classification code 10062547;Term: Congenital myopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Ventoline tablet 2mg
INN or Proposed INN: SALBUTAMOL SULFATE
Trade Name: Ventoline oral solution 0,4mg/ml
INN or Proposed INN: SALBUTAMOL SULFATE
Västra götalandsregionenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Phase 4Sweden